Cyfuse Biomedical K.K. (4892.T)
JPY 994.0
(-0.1%)
JPY 994.0
(-0.1%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -538.28 Million JPY | -53.38% |
| 2022 | -410.2 Million JPY | -308.1% |
| 2021 | 168.64 Million JPY | 158.42% |
| 2020 | -288.66 Million JPY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -209.95 Million JPY | 1.46% |
| 2024 Q1 | -221.56 Million JPY | -435.38% |
| 2023 Q4 | -51.54 Million JPY | 69.12% |
| 2023 FY | - JPY | -53.38% |
| 2023 Q3 | -166.9 Million JPY | 13.74% |
| 2023 Q2 | -193.49 Million JPY | -17.64% |
| 2023 Q1 | -164.47 Million JPY | -0.26% |
| 2022 FY | - JPY | -308.1% |
| 2022 Q4 | -164.05 Million JPY | -24.9% |
| 2022 Q3 | -131.34 Million JPY | 0.0% |
| 2021 FY | - JPY | 158.42% |
| 2020 FY | - JPY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 6.02 Billion JPY | 108.94% |
| Takeda Pharmaceutical Company Limited | 874.6 Billion JPY | 100.062% |
| Sumitomo Pharma Co., Ltd. | -281.07 Billion JPY | 99.808% |
| Shionogi & Co., Ltd. | 186.7 Billion JPY | 100.288% |
| Wakamoto Pharmaceutical Co.,Ltd. | 570.97 Million JPY | 194.276% |
| Nippon Shinyaku Co., Ltd. | 36.29 Billion JPY | 101.483% |
| Kaken Pharmaceutical Co., Ltd. | 12.26 Billion JPY | 104.388% |
| Eisai Co., Ltd. | 103.1 Billion JPY | 100.522% |
| Morishita Jintan Co., Ltd. | 1.29 Billion JPY | 141.631% |
| Hisamitsu Pharmaceutical Co., Inc. | 18.34 Billion JPY | 102.935% |
| Mochida Pharmaceutical Co., Ltd. | 8.97 Billion JPY | 105.999% |
| Fuso Pharmaceutical Industries,Ltd. | 3.67 Billion JPY | 114.667% |
| Nippon Chemiphar Co., Ltd. | 1.4 Billion JPY | 138.367% |
| Tsumura & Co. | 30.77 Billion JPY | 101.749% |
| Kissei Pharmaceutical Co., Ltd. | 18.72 Billion JPY | 102.875% |
| Torii Pharmaceutical Co., Ltd. | 5.27 Billion JPY | 110.212% |
| Towa Pharmaceutical Co., Ltd. | 35.53 Billion JPY | 101.515% |
| Fuji Pharma Co., Ltd. | 6.88 Billion JPY | 107.822% |
| Zeria Pharmaceutical Co., Ltd. | 17.52 Billion JPY | 103.072% |
| KYORIN Holdings, Inc. | 10.29 Billion JPY | 105.228% |
| Taiko Pharmaceutical Co.,Ltd. | -3.75 Billion JPY | 85.646% |
| Daito Pharmaceutical Co.,Ltd. | 7.55 Billion JPY | 107.127% |
| SymBio Pharmaceuticals Limited | -714 Million JPY | 24.609% |
| MedRx Co., Ltd | -884.51 Million JPY | 39.143% |
| Mizuho Medy Co.,Ltd. | 5.53 Billion JPY | 109.723% |
| Solasia Pharma K.K. | -635 Million JPY | 15.23% |
| Modalis Therapeutics Corporation | -2.37 Billion JPY | 77.325% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 9.16 Billion JPY | 105.875% |
| Sawai Group Holdings Co., Ltd. | 36.87 Billion JPY | 101.46% |
| Toho Holdings Co., Ltd. | 25.84 Billion JPY | 102.083% |
| Koa Shoji Holdings Co.,Ltd. | 5.1 Billion JPY | 110.551% |